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SUMMARY · Nowadays we may be overlooking an ever more common and most likely infectious
disease of uncertain etiology - prostatitis. The field of chronic prostatitis was stagnant for some three
decades, however, the state of affairs has changed dramatically over the last few years. Prostatitis is
the most common prostate disease in the younger population, which results in more physician visits
than either benign prostatic hyperplasia or prostate cancer. Despite its high prevalence, chronic pros-
tatitis as a disease and its etiology have been understudied. This article is concentrated on the entity
of chronic prostatitis, which is the most controversial, diagnostically most imprecise, and most frus-
trating diagnosis in medicine in general. Also, it is the most common ailment in men worldwide.
The knowledge about the disease is now progressing at a higher pace, especially concerning its eti-
ology and pathogenesis. Along with a review of the latest findings, an update is provided of the clas-
sification, diagnosis, treatment and epidemiology of chronic prostatitis. It is emphasized that the
disease should be recognized more often, or at least, epidemiologically speaking, it should be paid
more attention.
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Introduction
The field of prostatitis, especially chronic, was stag-
nant for three decades, however, the state of affairs has
changed dramatically over the last two years. Prostatitis
is the most common prostate disease, resulting in more
physician visits than either benign prostatic hyperplasia
or prostate cancer, according to the National Institutes of
Health, Bethesda, United States1. Despite its high preva-
lence, prostatitis as a disease and its epidemiology, espe-
cially its etiology, have been understudied2. Our under-
standing of the pathogenesis, etiology, diagnosis, and
treatment of chronic prostatitis has not advanced along
with that of other prostatic diseases. Recent articles and
scientific papers are focused on the entity and etiology of
chronic (idiopathic, abacterial) prostatitis. In this review,
we present the latest findings and guidelines on the epi-
demiology, etiology (microbiology), pathogenesis, classi-
fication and therapy of prostatitis, especially chronic, id-
iopathic prostatitis. The article is primarily based on the
research published over the last ten years.
Epidemiology
The state of the art on prostatitis suffers from many
gaps, beginning with the basic epidemiology of the dis-
ease.To discuss the epidemiology of prostatitis effectively,
an operational definition of prostatitis is essential. How-
ever, the task of defining prostatitis is difficult.
Prostatitis is the most common urologic diagnosis in
men under 50 years of age, and the third most common
in older men3. From 10% to 30% of men will have had a
diagnosis of prostatitis by 79 years of age4. The incidence
and prevalence are estimated to range between 5% and 8%.
The quality of health is similar to that in patients with
unstable angina, recent myocardial infarction, or active
Crohn’s disease. Thirty-five percent of men have symp-
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toms that could be diagnosed as prostatitis over a year. For
8%, it implies at least a minor problem3. According to
McNeal, a pathologist, the prostate gland is the internal
organ of the human body that is most commonly affected
by a disease5. The varying definitions of prostatitis reflect
in the broad range of estimates of epidemiological param-
eters reported in the literature. The histopathologic preva-
lence of prostatitis ranges from 35% to 98%, as summa-
rized by Bennett et al., or from 6% to 44%, according to
Roberts et al.4. Using data from the Olmsted County
Study of Urinary Symptoms and Health Status among
Men, they found the overall prevalence of the physician’s
diagnosis of prostatitis to be 11%. Only 4% of the nearly
2 million visits for prostatitis per year were recorded as
‘acute prostatitis’, suggesting that chronic prostatitis is
quite common4.
According to Stamey6, up to 50% of all men experi-
ence symptoms of prostatitis during the lifetime. A pros-
tatitis lesion was found in 40 (44%) of 91 men at random
autopsy7. In another study of 100 consecutive autopsies
in men killed in car accidents or died from other causes,
the prevalence of histologic signs of prostatitis increased
with age and was highest when benign prostatic hyper-
plasia was also present. Prostatitis was present in 22% and
60% of men under and over 40 years of age, respectively8.
Chronic Prostatitis and Benign
Prostatic Hyperplasia
The line between benign prostatic hyperplasia (BPH)
and prostatitis is blurred. Prostatitis as a histologic lesion
was found in 98% of patients with benign prostatic hy-
pertrophy9. Microbiological tests for BPH revealed high
rates of infectivity9. In another study, more than 70% of
transurethral resection of the prostate specimens showed
clinical or laboratory signs of infection10. BPH and pros-
tatitis cannot be distinguished according to symptoms,
and some believe that they may be the same disease. Many
publications have established the most common symp-
toms reported by men at visits for chronic prostatitis, com-
paring them with the results of visits for BPH. Pain was
more common than voiding complaints, and much more
common than sexual dysfunction among those visiting
physician for chronic prostatitis. In contrast, pain symp-
toms were a very infrequent reason for BPH visits. More-
over, the single most common reason for chronic prostati-
tis visits was painful urination, which was an uncommon
reason for BPH visits. These results suggested that pain
rather than urinary symptoms might discriminate chronic
prostatitis visits from BPH visits. This study also showed
that visits for chronic prostatitis were almost equally di-
vided between younger (aged 18 - 49 years) and older
(aged ³ 50 years) men. Finally, the investigators demon-
strated that chronic prostatitis not uncommonly coexisted
with the diagnosis of BPH; 9% of chronic prostatitis vis-
its were associated with both chronic prostatitis and BPH
diagnoses11. A limitation of these three studies, however,
is the potential unreliability of the physician’s diagnosis
of prostatitis.
National Institutes of Health
Classification of Prostatitis12,13
In 1995, the National Institutes of Health (NIH)
workshop on chronic prostatitis recognized the limited
understanding of the etiology for most patients previously
diagnosed as chronic prostatitis, and the possibility that
some organs other than the prostate gland may be impor-
tant in the pathogenesis of the syndrome. This meeting
developed by consensus a new classification system for
chronic prostatitis that addressed the concerns raised by
the participants and intended for use in clinical practice
and research studies. The NIH classifies prostatitis into
categories shown in Table 1. The new definition recog-
nizes that pain is the main symptom (with variable void-
ing and sexual dysfunction symptoms) and optimal cri-
terion to differentiate prostatitis patients from control
patients or patients experiencing other genitourinary
problems such as BPH. The definition of the chronic
prostatitis/chronic pelvic pain syndrome proposed by the
1995 NIH workshop on chronic prostatitis is based on
“the presence of genitourinary pain and the absence of
uropathogenic bacteria detected by standard microbio-
logical methodology”. This syndrome is further catego-
rized into inflammatory (based on the presence of leuko-
cytes in expressed prostatic secretion, postprostatic mas-
sage urine or semen), and noninflammatory (no signifi-
cant presence of leukocytes in similar specimens). Catego-
ries I and II are similar to the traditional classification of
acute and chronic bacterial prostatitis, respectively. The
new categories of chronic pelvic pain syndrome, inflam-
matory and noninflammatory (category III), and asymp-
tomatic and inflammatory prostatitis (category IV) ad-
dress the major problems and omissions of the traditional
and historical classification system. The adoption of a
standard definition and classification system should
G. ©timac et al. Chronic prostatitis · new prospects
Acta clin Croat, Vol. 40, No. 2, 2001 111
stimulate new and improved therapeutic initiatives in
chronic prostatitis research.
Etiology, Pathogenesis and Symptoms
Chronic prostatitis/chronic pelvic pain syndrome
· Dysfunctional high pressure voiding.
· Chronic bacterial prostatitis - recurrent urinary tract
infections associated with chronic infection of the
prostate gland. The condition usually responds (to
some extent) to antibiotics but tends to recur.
· Chronic prostatitis/chronic pelvic pain syndrome. Dis-
comfort or pain localized to the pelvis (genitourinary
discomfort or pain) for at least three months. There
is no associated bacterial infection and the condition
usually does not respond to antibiotics. The condi-
tion is associated with variable irritative and obstruc-
tive voiding symptoms.
· Intraprostatic ductal reflux.
· A microorganism based etiology.
· Acknowledged prostate pathogens - gram-negative
uropathogens (i.e. Enterobacteriaceae such as Escheri-
chia (E.) coli, Klebsiella sp., Pseudomonas sp., etc.).
· Probable prostate pathogens - gram-positive Entero-
coccus sp. (and Staphylococcus aureus).
· Possible prostate pathogens - coagulase negative
Staphylococcus, Chlamydia, Ureaplasma, anaerobes.
· Acknowledged prostate nonpathogens - Diphthe-
roids, Lactobacilli sp., Corynebacterium sp.
· Cryptic nonculturable organism - ‘biofilm bacteria’,
viruses, cell wall deficiency, etc.
· Autoimmune.
· Chemical - urine and its metabolites (i.e. uric acid).
· Neuromuscular.
· Interstitial cystitis.
Most urinary pathogens also are causative agents of
acute and chronic prostatitis. E. coli predominates as the
cause of culturable prostatitis. Other members of Etero-
bacteriaceae, such as Klebsiella, Enterobacteria, Proteus and
Serratia, can be isolated from patients with acute and
chronic prostatitis, as also can be Pseudomonas and less
commonly gram-negative bacteria. Obligate anaerobes
have rarely been implicated as the cause of prostatitis.
Gram-positive bacteria, particularly cocci, remain contro-
versial as the possible etiologic agents. E. coli is implicated
in 80% of infections6,14. Pseudomonas aeruginosa, Serratia,
Klebsiella and Proteus account for 10% - 15%, and entero-
cocci for 5% - 10% of cases15,16.
In their study Brunner et al. report that of 600 men
attending a special prostatitis clinic in Germany, 5% had
bacterial prostatitis, 64% had nonbacterial prostatitis, and
31% had prostatodynia17.
In the study of Lowentritt et al., coagulase-negative
staphylococci were the most common isolates (68%) in
chronic idiopathic prostatitis18. The role of Staphylococcus
epidermidis, the most commonly isolated organism, in the
etiology of chronic idiopathic bacterial prostatitis has also
been implicated by Nickel and Costerton19 and Wedren
Table 1. National Institutes of Health Classification of Prostatitis
Category I Acute bacterial prostatitis  Acute infection of the prostate gland
Category II Chronic bacterial prostatitis  Recurrent urinary tract infection
Chronic infection of the prostate
Category III Chronic abacterial prostatitis/ Discomfort or pain in the pelvic region (for at least three
Chronic pelvic pain syndrome months)/variable voiding and sexual symptoms
(CPPS) No demonstrable infection
Category IIIA Inflammatory chronic pelvic Significant white cells in semen/EPS/VB3
pain syndrome
Category IIIB Noninflammatory chronic Nonsignificant white cells in semen/EPS/VB3
pelvic pain syndrome
Category IV Asymptomatic inflammatory Evidence of inflammation in biopsy/semen/EPS/VB3
prostatitis (AIP) No symptoms
EPS=expressed prostatic secretion; VB3=third voided urine specimen
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et al.20. Another coagulase-negative staphylococcus spe-
cies isolated in this study, Staphylococcus haemolyticus, has
been reported by Gunn and Davis21 and Sanchis-Bayarri
et al.22 to cause urinary tract infection in men.
A large study including 597 prostatitis patients showed
prostatodynia to be diagnosed in nearly one third of them,
which is a significant portion of the urologic population17.
Recent literature data suggest that the condition referred
to as chronic idiopathic (nonbacterial) prostatitis may
actually have an infectious etiology18,19,23-26. Some pa-
tients relate the onset of their symptoms to sexual activ-
ity27, sometimes associated with acute urethritis, while
others have indicated no relationship with sexual activity.
An underlying anatomical or functional condition usually
complicates urinary tract infections in men, however,
noncomplicated infections, often related to sexual activ-
ity do occur as well14,27.
The role of mycoplasmal, ureaplasmal and chlamydial
species in the etiology of the disease is centered on the
chronic pelvic pain syndromes28. A number of organisms
have been reported to possibly cause the syndrome, e.g.,
Trichomonas vaginalis29-32, Chlamydia trachomatis9,33-36,
genital mycoplasmas17,37, staphylococci19,34,38, coryne-
forms23,39, and genital viruses40,41. Researchers from Ja-
pan suggest that Chlamydia trachomatis often is the caus-
ative organism in chronic idiopathic prostatitis42.
Although Ureaplasma urealyticum has long been im-
plicated as sometimes causing nongonococcal urethritis,
its role as an etiologic agent of prostatitis is controversial.
Common pathogens and unconventional, fastidious bac-
teria, viruses, parasites and fungi are causative agents in
male urethroadnexitis. Uropathogens and sexually trans-
mitted organisms must be considered43. Bowie et al. re-
port that the most important causes of urinary tract in-
fection in younger men are Chlamydia trachomatis and
Neisseria gonorrhoeae, while the most important causes of
prostatitis and epididymitis in older men or men with
urethral structural abnormalities are classical urinary tract
pathogens rather than sexually transmitted pathogens27.
The ascending spread of urethral pathogens may be the
mechanism of infection of the prostate and epididymis.
Brunner et al. found Ureaplasma urealyticum to be positive
in high numbers of expressed prostatic secretions and
urine voided after prostatic massage in 82 (13.7%) of 597
patients with chronic prostatitis17. As the number of
ureaplasmas in first-voided urine and midstream urine was
significantly lower, the source of the organisms in these
patients was assumed to be the prostate. These data and
results of tetracycline treatment provide sufficient evi-
dence for the etiologic importance of ureaplasmas in
chronic prostatitis. Sexually transmitted organisms are the
most common cause of epididymitis in young men, and
evidence is accumulating suggesting that sexually trans-
mitted organisms may cause prostatitis44. It has been defi-
nitely demonstrated that Ureaplasma urealyticum is an
etiologic agent of nongonococcal urethritis, a sexually
transmitted disease. For this reason, it seemed possible
that the organism might cause ascending inflammatory
reactions of the prostate. In addition to the well known
urinogenic enterobacteriae and enterococci, and the sexu-
ally transmitted gonococci and trichomonas, Chlamydia
trachomatis and Ureaplasma urealyticum should now be
considered particularly important etiologic agents that
also are sexually transmitted37,45.
Many studies suggest that either an agent as yet uni-
dentified or multiple agents may be involved in the etiol-
ogy of nonbacterial prostatitis46. According to some au-
thors, acute prostatitis results from ascending urethral
infection6,47, and from reflux of infected urine into pros-
tatic ducts16,48.
Diagnosis and Therapy
The National Institutes of Health Chronic Prostati-
tis Symptom Index (NIH-CPSI), available online at
http://www.QLMed.org/nih-cpsi/, accurately measures
the three major domains of the chronic prostatitis syn-
drome: pain, voiding dysfunction, and impact/quality of
life. The NIH-CPSI provides a valid outcome measure for
men with chronic prostatitis. It is as useful in research as
in clinical practice to follow up patients with chronic pros-
tatitis/chronic pain syndrome. We have concluded that the
symptom index is not very suitable when working with our
outpatients. Culture diagnosis of acute bacterial prostatitis
is straightforward and easily accomplished in the labora-
tory. On the other hand, the microbiological diagnosis of
chronic prostatitis and chronic idiopathic (nonbacterial)
prostatitis (more commonly referred to as prostatodynia)
is a major challenge. Chronic idiopathic prostatitis, when
diagnosed clinically, has a poor record of treatment suc-
cess. The major difficulty in interpreting microbiological
findings is the presence of contaminating, indigenous
microbiota. Specimens such as voided urine, urethral
swabs, and expressed prostatic secretions used to evalu-
ate a patient with suggestive symptoms become contami-
nated with the organisms colonizing the distally contami-
nated urethra. Although an ideal specimen would be un-
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contaminated prostatic tissue, there are few such reports
in the literature. The microbiological workup of these
specimens is further complicated by the presence of in-
hibitory substances known to exist in the prostatic secre-
tions, and the history of multiple previous courses of an-
tibiotics.
The quantitative bacteriological cultures confirm the
diagnosis of bacterial prostatitis when the infectious
agent(s) is localized to the prostate gland (i.e. segmented
cultures). The technique of obtaining segmented cultures
of the male lower urinary tract was first described in 1968
by Meares and Stamey16 (Table 2). This method, although
rarely used today in clinical practice, is still by many con-
pear to have abandoned the procedure because of its la-
bor intensity and overall costs. In 1999, Nickel49 proposed
a simple and cost-effective screen for prostatitis, which
includes culture and microscopic examination of urine
before and after prostatic massage (see Table 2). This pre-
and postmassage test (PPMT) was used in a series of 53
patients and in 59 patients whose segmented culture re-
sults were available from the literature. In these selected
populations, the PPMT alone led to the same diagnosis
in 102 (91.1%) patients. Within the expected limitations
of this retrospective review, the calculated sensitivity and
specificity of PPMT were 91% each. It is important that
physicians might be ready to adopt the simpler diagnos-
Table 2. Interpretation of four- and two-glass tests (lower urinary tract localization studies)
Test Four-glass test pre- and postmassage test
(Meares and Stamey, 1968)  (PPMT; Nickel, 1999)
Specimen VB1 VB2 EPS VB3 Pre-M Post-M
Category II WBC - +/-* + + +/-* +
Culture - +/-* + + +/-* +
Category IIIA WBC - - + + - +
Culture - - - - - -
Category IIIB WBC - - - - - -
Culture - - - - - -
Category=National Institutes of Health Classification Category (Table 1); WBC=white blood cells; VB1=first voided
urine specimen; VB2=second voided urine specimen or midstream specimen; EPS=expressed prostatic secretion;
VB3=third voided urine specimen; Pre-M=urine specimen before prostate massage; Post-M=urine specimen after pros-
tate massage.
sidered the ‘gold standard’ for localizing the prostate gland
infection. The sampling conditions require a sufficiently
full bladder, and the samples must be collected by using
rigorous aseptic technique. The first step of the examina-
tion must not be preceded by urethral swabbing. Prostatic
secretions are obtained by systematic massage of each lobe
of the prostate gland. Bacterial prostatitis is confirmed by
the presence of bacteria in the prostatic secretions and in
the VB3 (voided bladder) postprostatic massage urine
sample in numbers greatly exceeding the bacterial counts
of the VB1 and VB2 urine specimens. The traditional
criterion for diagnosing chronic bacterial prostatitis is a
10-fold increase in the concentration of culturable micro-
organisms, when the bacterial count of the postmassage
urine sample or expressed prostatic secretion sample is
compared with that of the first void (VB1) urine sample16.
The segmented culture technique is not widely used
in primary care settings, the more so, most urologists ap-
tic plan for prostatitis because it is by far more efficient
in terms of diagnosing the disease than doing no workup
for infection localization.
The men with the symptoms of prostatitis must be
evaluated by both urine and prostatic secretions to docu-
ment the infection and inflammation. A majority of men
with such symptoms do not have an infection that can be
documented. These men respond poorly to medication.
The men with documented chronic bacterial prostatitis
require long courses of antimicrobials for effective cure.
In some cases, however, the disease is intractable, and
chronic suppression with antimicrobials may be necessary.
Chronic prostatitis causes considerable morbidity for
many men. Specific therapy leads to cure and improve-
ment for patients with infectious causes. However, the
treatment is frequently empirical and unsatisfactory, be-
cause we have limited understanding of the causes and
pathophysiology of these neglected disease syndromes.
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Cryptic microorganisms may be important in some cases.
Defining the precise role for such organisms will require
better diagnostic algorithms and methods to elucidate the
microbiology of the prostate in health and disease. Table
3 shows the treatment of prostatitis syndromes for catego-
ries I through IV.
NIH category I (acute bacterial prostatitis): The pros-
tate should not be massaged. Pain killers and stool soft-
eners are prescribed along with adequate hydration of the
patient. Suprapubic catheter is inserted if the patient de-
velops urinary retention. If the patient is admitted, he is
treated with parenteral antibiotics (aminoglycoside +
ampicillin/third generation cephalosporin), whereas
sulfamethoxazole + trimethoprim or fluoroquinolone
(cipro/levaquin) are used when the treatment is advised
on outpatient basis. Antibiotic therapy is given for 2-4
weeks. A poor response to this treatment may be due to
the development of prostatic abscess (can be demonstrated
on US/CT scan), which, if documented, can be drained
by transurethral/transperineal route.
NIH category II (chronic bacterial prostatitis): It is
treated by sulfamethoxazole + trimethoprim (for 10 weeks;
30% cure rate) or fluoroquinolones (norfloxacin/cipro-
floxacin for 4-6 weeks; 75% cure rate) or a low dose sup-
pressive therapy (TMP-SMX/nitrofurantoin/tetracy-
cline/cephalothin). Some patients with this condition
(those not responding to antibiotic therapy) may require
surgical debridement (removal of all infective foci/stones
by radical transurethral resection of the prostate).
NIH category IIIA (chronic abacterial prostatitis): It
is treated by pain killers and a 1-month trial of TMP-
SMX or ofloxacin or tetracycline. However, the condition
is commonly treated by prostatic massage. Alpha blockers
(terazosin) are useful in relieving pain and voiding symp-
toms often seen in these patients. Newer forms of therapy
such as finasteride (in old patients with boggy prostate),
pentosan polysulfate (in those with suprapubic pain and
irritative voiding symptoms), phytotherapy (saw palmetto
extract) and transurethral thermotherapy are currently
being studied in these patients.
NIH category IIIB (prostatodynia): These patients
are treated with pain killers and anti-inflammatory agents.
Alpha blockers are used to relieve pain and improve void-
ing symptoms. Muscle relaxants such as diazepam are also
helpful. These patients also benefit from supportive
therapy such as perineal massage, relaxation therapy,
perineal support and perineal heat fomentation.
NIH category IV (asymptomatic inflammatory pros-
tatitis): No specific treatment is required in these patients
except when there is elevation of PSA or infertility.
Conclusions
Prostatitis (more often chronic, idiopathic) is a com-
mon urologic condition that many clinicians find difficult
to diagnose, and especially to treat effectively. Culture di-
agnosis of acute bacterial prostatitis is straightforward and
easily accomplished in the laboratory, and nowadays does
not represent a problem in practice anymore. On the other
hand, the microbiological and clinical diagnosis of chronic
prostatitis and especially chronic (nonbacterial) prostati-
tis (more commonly referred to as chronic pelvic pain
syndrome in men) represents considerable challenge.
Chronic prostatitis is the most controversial, most impre-
Table 3. Treatment of prostatitis syndromes
Category I Category II Category IIIA Category IIIB Category IV
I.v. antibiotics +/- Antibiotics +/- Antibiotic trial +/- Triple therapy: No treatment
catheterization prostate massage prostate massage alpha blockers indicated (unless
Follow-up: Follow-up: +/- alpha blockers muscle relaxants elevated PSA or
oral antibiotics antibiotics +/- finasteride analgesics infertile)
(suppressive, +/- phytotherapy +/- tricyclic
prophylactic) + lifestyle changes antidepressants
surgery? +/- biofeedback
+ lifestyle changes
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cise, and most frustrating diagnosis in medicine in gen-
eral. It is also the most common ailment in men world-
wide. The mode of transmission has been linked to uri-
nary tract infection and more recently as being sexually
acquired. Urinary tract infection has been taken for
granted and its mode of transmission ignored. Many re-
cent studies suggest that sexually transmitted organisms,
e.g., Chlamydia, Ureaplasma, etc. (as mentioned above in
the article), may cause prostatitis. We think it should be,
at least epidemiologically and therapeutically, paid more
attention. Ever more evidence and studies have been ac-
cumulating suggesting that nonculturable organisms may
cause prostatitis. In this article, we do not bring any defi-
nite conclusions, but have tried to provide and update on
prostatitis (especially chronic, idiopathic) as a rising prob-
lem in urology considering its prevalence, epidemiology,
probable causative agents involved, and treatment out-
come.
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SAÆETAK
NOVI IZGLEDI ZA KRONI»NI PROSTATITIS
G. ©timac, J. Dimanovski i A. ReljiÊ
Danas moæda previðamo prostatitis, sve Ëe¹Êu i najvjerojatnije zaraznu bolest neutvrðene etiologije. PodruËje kroniËnog
prostatitisa stagniralo je kroz nekoliko desetljeÊa, da bi se stanje dramatiËno promijenilo posljednjih nekoliko godina. Prostatitis
je najËe¹Êa bolest prostate u mlaðoj populaciji, koja rezultira veÊim brojem lijeËniËkih pregleda nego benigna hiperplazija prostate
ili rak prostate. Usprkos uËestalosti kroniËnog prostatitisa, premalo je istraæivanja kroniËnog prostatitisa kao bolesti, kao i njegove
etiologije. Ovaj je Ëlanak usredotoËen na entitet kroniËnog prostatitisa, koji predstavlja najkontroverzniju, najneprecizniju i najvi¹e
zbunjujuÊu dijagnozu u Ëitavoj medicini. To je takoðer najËe¹Êa bolest u mu¹karaca ¹irom svijeta. Danas se sve bræe pobolj¹avaju
saznanja o ovoj bolesti, poglavito o njezinoj etiologiji i patogenezi. Prikazan je pregled najnovijih nalaza i saznanja o klasifikaciji,
dijagnostici, lijeËenju i epidemiologiji kroniËnog prostatitisa. Isto tako, smatramo kako bi ovu bolest trebalo vi¹e uvaæavati ili joj
barem s epidemiolo¹kog stajali¹ta poklanjati vi¹e pozornosti.
KljuËne rijeËi: Prostatitis, etiologija; Prostatitis, terapija; KroniËne bolesti, epidemiologija
